Bluejay Diagnostics Allereye Tear Total IgE Test Receives CE Mark

Bluejay Diagnostics announced that it has received CE Mark for the Allereye Tear Total IgE Test.  Allereye, an FDA-Cleared point-of-care (POC) device, offers healthcare providers a cost-effective, non-invasive, reliable, easy-to-use solution to aid in the diagnosis of allergic conjunctivitis. Bluejay expects to launch the product in Q2 of 2019 throughout Europe and the Middle East.

Allereye confirms the presence of total IgE in tears. Developed on a unique design and technology platform, Allereye offers non-invasive and rapid (15 minutes) POC detection of IgE in the aid to diagnose allergic reactions in the eye. Such detection at point-of-care might prevent unnecessary dry-eye treatment and unnecessary antibiotic regimen.

Svetlana Dey, President of Bluejay, added, “After receiving very positive feedback from U.S. clinicians and patients, we are confident that Allereye will bring the same value to the patient population throughout Europe and the Middle East.”

Interest in conjunctivitis commonly known as ‘red-eye’ has increased in recent years due to its growing prevalence, increasing healthcare costs, and its impact on patient quality of life. Often allergic, viral, and bacterial related ‘red-eye’ have similar symptoms leading to an inaccurate diagnosis more than half of the time and resulting in unnecessary time away from work, school and play.

Currently about two out of every five people worldwide suffer from allergic conjunctivitis. Itchy eyes are the most common symptom. Seasonal allergic conjunctivitis is the most common form as symptoms are associated with specific aeroallergens. Perennial allergic conjunctivitis persists throughout the year and is often caused by dust mites, molds and pet dander.

Medical Device News Magazine
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Thermo Scientific™ Dionex™ Inuvion™ Ion Chromatography (IC) system, helping to make ion analysis simpler and more intuitive for labs of all sizes. The new analytical instrument is designed to be easily reconfigurable, providing those who require determination of ionic and small polar compounds with a one stop shop for consistent, reliable ion analysis.
This new collaboration is another example of Blacksmith's creative deal-making with top tier partners that bring expertise to the table which helps de-risk and accelerate scientific discoveries for the development of valuable products.
Heparin Sodium 2,000 units in 0.9% Sodium Chloride Injection 1,000 mL (2 units/mL), is indicated as an anticoagulant to maintain catheter patency.
Through this agreement, RaySearch acquires full ownership of all rights to the product DrugLog for its application in the field of oncology, including the measuring device, calibration parameters, source code, as well as intellectual property rights.
Anna Kazanchyan, MD, Founder and CEO of Saghmos Therapeutics. "We are very pleased to announce the Notice of Allowance for our second patent, which will enhance the long-term value of ST-62516. Saghmos continues to build its intellectual property estate."

By using this website you agree to accept Medical Device News Magazine Privacy Policy